G
Gianfranco Delle Fave
Researcher at Sapienza University of Rome
Publications - 154
Citations - 7382
Gianfranco Delle Fave is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Neuroendocrine tumors & Pancreatitis. The author has an hindex of 43, co-authored 151 publications receiving 6540 citations. Previous affiliations of Gianfranco Delle Fave include University of Verona & University of Rome Tor Vergata.
Papers
More filters
Journal ArticleDOI
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
Martyn Caplin,Eric Baudin,Piero Ferolla,P.L. Filosso,Mariano García-Yuste,Eric Lim,Kjell Öberg,Giuseppe Pelosi,Aurel Perren,Roberta Elisa Rossi,Roberta Elisa Rossi,William D. Travis,Detlief Bartsch,Jaume Capdevila,Frederico Costa,Jarosław B. Ćwikła,Wouter W. de Herder,Gianfranco Delle Fave,Barbro Eriksson,Massimo Falconi,Diego Ferone,David J. Gross,Ashley B. Grossman,Tetsuhide Ito,Robert T. Jensen,Gregory Kaltsas,Fahrettin Kelestimur,Reza Kianmanesh,Ulrich Knigge,Beata Kos-Kudła,Eric P. Krenning,Emmanuel Mitry,Marianne Nicolson,Juan Manuel O'Connor,Dermot O'Toole,Ulrich Frank Pape,Marianne Pavel,John Ramage,Eric Raymond,Guido Rindi,Andrea Rockall,Philippe Ruszniewski,Ramon Salazar,Aldo Scarpa,Eva Sedlackova,Anders Sundin,Christos Toumpanakis,Marie Pierre Vullierme,Wolfgang Weber,Bertram Wiedenmann,Zeng Zheng-Pei +50 more
TL;DR: PCs are complex tumors which require a multidisciplinary approach and long-term follow-up, and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC.
Journal ArticleDOI
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia,Irene Dalai,Stefano Barbi,Stefania Beghelli,Massimo Falconi,Marco Della Peruta,Lorenzo Piemonti,Gabriele Capurso,Alessia Di Florio,Gianfranco Delle Fave,Paolo Pederzoli,Carlo M. Croce,Aldo Scarpa +12 more
TL;DR: The results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors and raises the potential for SSTR expression to be evaluated as a marker of response to somatostatin analogs.
Journal ArticleDOI
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
Francesco Panzuto,Silvia Nasoni,Massimo Falconi,Vito D. Corleto,Gabriele Capurso,S. Cassetta,Michela Di Fonzo,Valentina Tornatore,Massimo Milione,Stefano Angeletti,Maria Sofia Cattaruzza,Vincenzo Ziparo,Cesare Bordi,Paolo Pederzoli,Gianfranco Delle Fave +14 more
TL;DR: Although 64.3% of gastro-entero-pancreatic endocrine tumors present metastases at diagnosis, the 5-year survival rate is 77.5%, and pancreatic site, the poor degree of differentiation and distant extra-hepatic metastases are the major negative prognostic factors.
Journal ArticleDOI
Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.
Marco Centanni,Lucilla Gargano,Gianluca Canettieri,N Viceconti,Antonella Franchi,Gianfranco Delle Fave,Bruno Annibale +6 more
TL;DR: Patients with impaired acid secretion require an increased dose of thyroxine, suggesting that normal gastric acid secretion is necessary for effective absorption of oral thyrotropin.
Journal ArticleDOI
ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms
Gianfranco Delle Fave,Dik J. Kwekkeboom,Erik Van Cutsem,Guido Rindi,Beata Kos-Kudła,Ulrich Knigge,Hironobu Sasano,Paola Tomassetti,Ramon Salazar,Philippe Ruszniewski +9 more
TL;DR: This research presents a meta-analyses of the immune system’s response to chemotherapy, which shows clear patterns of decline in the immune systems of patients with symptomatic oncologists and patients with a history of liver disease.